Clinical Trial Update: A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins [Phase 2]

View source ↗

Summary

Phase 2 multiple-dose study of PF-04950615 (RN316) in patients on high-dose statins has completed, with results posted on 2017-10-11.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hypercholesterolemia

Drugs mentioned

• PF-04950615 (RN316) (PF-04950615)

Snippet

Sponsor: Pfizer | Conditions: Hypercholesterolemia, Dyslipidemia | Phase 2 | Status: COMPLETED | Results posted: 2017-10-11